research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
Search
for
Sort by
Research
270-300 / 1000+ results
research Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles
Mesenchymal stem cells may help treat hair loss by improving hair cell growth and reducing inflammation.
research Rapidly Progressive Alopecia Areata Totalis in a COVID-19 Patient, Unresponsive to Tofacitinib
A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
research Response of Alopecia Areata of the Beard to Oral Tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Interleukin 6 and STAT3 Regulate p63 Isoform Expression in Keratinocytes During Regeneration
The conclusion is that the IL-6/STAT3 activation affects p63 expression in healing wounds, which may help in hair follicle regeneration.
research Balance of Tofacitinib Efficacy and Disease Flare in the Treatment of Alopecia Universalis: A Case Report and Review of the Literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Tofacitinib for the Treatment of Three Immune-Mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Apremilast and Tofacitinib Exert Differential Effects in the Humanized Mouse Model of Alopecia Areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib treatment for hair loss may worsen acne.
research Biologics in the Management of Childhood Atopic Dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Peripheral Neuropathy Associated with Tofacitinib Use in Alopecia Universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Tofacitinib Treatment in Children With Rheumatic Diseases: Single-Center Experience
Tofacitinib is a promising treatment for children with rheumatic diseases.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Steroid-Free Monotherapy with Tofacitinib in Severe Therapy-Resistant Alopecia: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: Evidence to Date
Baricitinib is a promising treatment for alopecia areata.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
research Use of Tofacitinib in Difficult to Treat Clinically Amyopathic Dermatomyositis
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research A Retrospective Review of Pediatric Alopecia Areata Cases Seen in a Tertiary Institution in Singapore
Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Drug Armamentarium for Alopecia Areata
No cure exists for alopecia areata, and treatments are personalized.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research Review of the Literature: Topical JAK Inhibitors Showing Promise for Hair Loss
Topical JAK inhibitors may help treat hair loss.
research Baricitinib-Loaded EVs Promote Alopecia Areata Mouse Hair Regrowth by Reducing JAK-STAT-Mediated Inflammation and Promoting Hair Follicle Regeneration
Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
research Treatment of Refractory Folliculitis Decalvans With the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.